Skip to main content
OpenTrials
Completed

NCT Number: NCT05247385

Platelet Aggregation and Adenosine Levels Among Patients Taking Ticagrelor or Prasugrel

Prospective, single-center, double blind, double dummy, randomized trial. Platelet function tests and adenosine levels were assessed at baseline and 15 days after taking Ticagrelor with Prasugrel placebo or Prasugrel with Ticagrelor placebo in stable patients with coronary artery disease

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Coronary Artery Disease Arterial Occlusive Diseases Arteriosclerosis Cardiovascular Diseases Coronary Disease Heart Diseases Myocardial Ischemia Vascular Diseases

Age range

18 year–75 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

Heart Institute (InCor) / University of São Paulo

São Paulo, 05403-000, Brazil

About this study

This was a prospective, double blinded, randomized trial that compared platelet inhibition and adenosine levels with ticagrelor (180mg loading dose, followed by 90 mg BID) versus prasugrel (60mg loading dose, followed by 10 mg QD) .

Patients were eligible if they were between 18 and 75 years old, were on aspirin without P2Y12 inhibitor at baseline and > 1 year after documented ACS. Platelet aggregation was compared with the Multiplate ADP® assay, performed at baseline and after 15 days on study medication. Adenosine plasma levels were measured with high performance liquid chromatography at the same time points

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • between 18 and 75 years old
  • were on aspirin
  • without P2Y12 inhibitor at baseline
  • > 1 year after documented acute coronary syndrome

Exclusion criteria

  • use of oral anticoagulation or P2Y12 at baseline
  • Weight < 60kg
  • History of tia or stroke
  • Any coagulation disorders
  • Refuse to sign the written consent

Treatment and study plan

Prasugrel

Drug

Compared platelet inhibition and adenosine levels at baseline and after 15 days

Ticagrelor

Drug

Compared platelet inhibition and adenosine levels at baseline and after 15 days

Primary outcomes

  1. To compare platelet inhibition between the two groups (ticagrelor and prasugrel)

    Time frame: 15 days

    Platelet aggregation was compared with the Multiplate ADP® assay at baseline and after 15 days on study medication

  2. To compare adenosine levels between the two groups (ticagrelor and prasugrel)

    Time frame: 15 days

    Adenosine plasma levels were measured at baseline and after 15 days with high performance liquid chromatography at the same time points

Sponsors and collaborators

Lead sponsor

University of Sao Paulo

Other

Registry information

Official study title

Platelet Aggregation and Adenosine Levels Among Patients With Stable Chronic Coronary Artery Disease Taking Ticagrelor or Prasugrel

Important dates

Study start
2017
Primary completion
2021
Study completion
2021
First posted
Feb 18, 2022
Registry last updated
Feb 18, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.